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Celiac disease (CD) is an enteropathy triggered by the ingestion of
gliadin and of other related prolamines in genetically predisposed
individuals [1,2]. Gliadin peptides exert damaging effects through
various mechanisms: they are resistant to gastrointestinal enzymes
[3], they have amino acid sequences that are speciﬁc for human
leukocyte antigen (HLA)-DQ2, which is a class II major histocompat-
ibility complex, they also have preferred glutamine residues for tissue
transglutaminase (tTG)-mediated deamidation [4], and, lastly, they
affect intestinal permeability [5]. Some gliadin peptides are toxic and
others are immunogenic for CD patients [5]. Toxic gliadin peptides
exert direct effects on cells. In particular, they can agglutinate
undifferentiated K562, can maintain tissue damage in the intestinal
mucosa of CD patients, and can activate innate immune mechanisms
in patients on a gliadin-free diet [6–8]. On the other hand,
immunogenic gliadin peptides, after passing the intestinal epithelial
border, trigger a dysregulated adaptive immune response at gut level
dominated by T cells of the T helper 1 type. However, the innate andadaptive immune systems may respond synergistically to gliadin
peptides [5–7]. The prototype of peptides effective on innate response
is peptide 31–43/49, which has been shown to be toxic for CD patients
both in vitro and in vivo [8,9]. Peptide 31–43 (p31–43) stimulates the
synthesis and release of the proinﬂammatory cytokine IL-15 that can
promote an adaptive immune response [6] involving CD4+T cells that
recognize various deamidated gliadin peptides [4]. Unlike p31–43
which is not immunogenic for T cells, peptide 57–68 (p57–68), which
binds to HLA-DQ2/8 molecules, is one of the dominant epitopes
recognized by T cells isolated from the intestine of CD patients [4].
Celiac disease is considered an autoimmune disease because of the
presence of tTG-targeting autoantibodies in the serum and the
intestinal mucosa of patients. tTG is a ubiquitously expressed
multifunctional protein [10] that prevalently catalyzes the formation
of isopeptide linkages between the γ-carboxamide group of protein-
bound glutamine residue and the ε-amino group of protein-bound
lysine residue. Glutamine residues can be deamidated to glutamic acid
as a side-reaction in the absence of suitable amines or at low pH.
Furthermore, tTG is capable of both binding and hydrolyzing GTP, so
that the enzyme can function as a cell signal transducer in association
with the α1β-adrenoreceptor [11]. Also disulfide isomerase activity
[12] and kinase activity [13] have been attributed to tTG.
In CD, anti-tTG autoantibodies are produced in the small-intestinal
mucosa and are deposited in the small bowel mucosa below the
basement membrane and around capillaries in untreated patients
[14,15]. Interestingly, even seronegative patients have these mucosal
anti-tTG deposits when on a gluten-containing diet [16]. During
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serum of patients and slowly disappear from the circulation con-
sequent to a gluten-free diet [17]. After a gluten-free diet, serum
autoantibodies disappear from the circulation more rapidly than do
the small-intestinal mucosal autoantibody deposits [14,15].
It is now recognized that anti-tTG antibodies are functional and
not mere bystanders in the pathogenesis of CD. In fact, they inhibit
intestinal epithelial cell differentiation [18], increase epithelial
permeability and activate monocytes [19], and impair angiogenesis
[20]. Moreover, we previously demonstrated that anti-tTG antibodies
induce intestinal epithelial cell proliferation [21]. Interestingly, the
effect of epithelial cell proliferation evoked by anti-tTG antibodies is
similar to the effect evoked by some gliadin peptides [22]. In
particular, p31–43, but not p57–68, causes actin alterations and cell
proliferation, both of which depend on activation of the epidermal
growth factor (EGF)-receptor, in several cell types, and in organ
culture of celiac mucosa [22]. These effects of gliadin peptides are
regarded as non-T-cell mediated, and most likely play an important
role in the very early phases of CD. However, little is known about the
mechanism underlying p31–43 and p57–68 uptake into cells [23].
The aim of this study was to investigate the relationship between
anti-tTG antibodies and gliadin peptides, both of which are present in
the small-intestinal mucosa of patients in the early phase of CD.
2. Materials and methods
2.1. Antibodies and peptides
The commercial monoclonal tTG-antibody clone CUB 7402
(200 μg/ml) was from NeoMarkers (Freemont, CA, USA). The
recombinant anti-tTG miniantibody (clone 2.8) was derived from a
library of CD intestinal lymphocytes [24]. The cloning and puriﬁcation
procedure is reported elsewhere [25]. Control antibodies were non-
speciﬁc mouse IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA).
Unlabeled and lissamine-labeled synthetic peptides were from Inbios
(Naples, Italy). The sequences of p31–43 and p57–68 from α-gliadin
were LGQQQPFPPQQPY and QLQPFPQPQLPY, respectively.
2.2. Cell culture
Caco-2 cells were cultured in 100×10-mm Petri dishes containing
Dulbecco's modiﬁed Eagle's medium supplemented with 10% (v/v)
fetal bovine serum (FBS), 1% (v/v) non-essential amino acids, 0.2 mM
L-glutamine, 50 units/ml penicillin and 50 μg/ml streptomycin (Invi-
trogen SRL, Milan, Italy). Cells were maintained at 37 °C in a 5% CO2,
95% air-humidiﬁed atmosphere and passaged twice a week.
2.3. Cell staining
The localization of tTG in non-permeabilized living cells seeded on
glass coverslips was determined by incubating cells with 20 μg/ml of
clone 2.8 in 1% bovine albumin in phosphate-buffered saline (PBS)
and with a mouse secondary TRITC-conjugated antibody (1:50). After
ﬁxing with 3% paraformaldehyde (PFA) for 10 min, coverslips were
washed several times with PBS and mounted with Moviol (Sigma-
Aldrich, Milan, Italy). Stained cells were observed with an Axioplan 2
ﬂuorescent microscope (Carl Zeiss MicroImaging, Inc., Jena,
Germany). Images were acquired and processed with the KS300
software (Carl Zeiss MicroImaging Inc.).
2.4. S-phase entry assay
The bromodeoxyuridine (BrdU) (Roche Diagnostics SpA, Monza,
Italy) incorporation study was carried out as reported elsewhere [21]
with some modiﬁcations. Brieﬂy, Caco-2 cells were seeded on
coverslips and, 24–48 h later, starved by culturing cells in 0.1% FBSmedium for 72 h. Cells were then challenged with antibodies to tTG,
or control antibodies, or gliadin peptides, for 24 h. 10% FBS was used
as positive control. Three hours before PFA ﬁxing and triton X-100
permeabilizing, BrdU was added to the medium (ﬁnal concentration,
100 μM). BrdU incorporation was monitored by treating cells with an
anti-BrdU antibody 1:100 (Invitrogen) and a mouse secondary TRITC-
conjugated antibody (Invitrogen) 1:100. Finally, cells were stained for
5 min with Hoechst (Sigma-Aldrich) and mounted with Moviol. The
number of cells that entered into S-phase was expressed as the ratio
between the number of cells incorporating BrdU and the total number
of cells. Microscope observations were carried out as reported above.
Over 300 cells in several ﬁelds were evaluated in each sample.2.5. In vitro tTG assay
Enzyme activity was assayed by a radiometric method based on
Ca2+-dependent incorporation of [3H]spermidine (Nen Life Science
Products, Boston, MA, USA) into N,N-dimethylated casein, as reported
elsewhere [26]. Cellular extract from Caco-2 cells (15 μg) was used as
enzymatic source and incubated without (basal activity) and with
antibodies and amines at 37 °C for 30 min.2.6. Immunoprecipitation of surface tTG from Caco-2 cell membranes
We used the immunoprecipitation strategy (slightly modiﬁed)
reported by Akimov et al. [27]. Brieﬂy, Caco-2 cells (about 20×106)
were extensively washed with PBS without calcium and magnesium,
and detachedwith 0.5% EDTA to preserve surface tTG.We biotinylated
the cell surface using PBS containing 4 mM Sulfo-NHS-Biotin (Pierce,
Milan, Italy) for 30 min at room temperature, and the reaction was
quenched with 100 mM glycine in PBS. After washing with PBS, cells
were disrupted by osmotic shock in deionized water and the cell
membrane fraction was enriched by centrifugation (14,000×g for
90 min). Pellets were resuspended in 0.25 ml of RIPA buffer (50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 5 mM
MgCl2, 0.1% sodium dodecyl sulfate, 1% triton X 100, 0.5 mM
phenylmethylsulfonyl ﬂuoride, 1 mM ortovanadate, 10 μg/ml leu-
peptin, 10 μg/ml aprotinin [Sigma-Aldrich]), or in the same buffer
without sodium dodecyl sulfate and triton X 100 but containing 0.1%
Nonidet P-40 (Sigma-Aldrich), for 30 min at 4 °C. An aliquot of the
extracted proteins was tested in an ELISA assay to verify the presence
of a biotinylated protein that could be recognized by antibody clone
2.8 (not shown). The remaining surface proteins were immunopre-
cipitated with CUB 7402 (3.0 μg) or clone 2.8 (3.0 μg). Mouse IgG
(3.0 μg) was used in control immunoprecipitation.2.7. Western blot
For the detection of the phosphorylated form of extracellular
signal-regulated kinase (P-ERK), cell lysates were prepared as
described previously [28], as well as electrophoresis and immuno-
blotting procedures [28]. P-ERK was detected using anti-P-ERKmouse
monoclonal antibody (clone E4, Santa Cruz). Total ERK was detected
using ERK rabbit polyclonal antibody anti-ERK K23 (clone K23, Santa
Cruz). The samples resulting from immunoprecipitation experiments
were separated by 10% sodium dodecyl sulfate gel electrophoresis and
transferred to a membrane. Biotinylated proteins were visualized on
the blot with horseradish peroxidase-conjugated streptavidin 1:2000
(Pierce) according to the procedure described elsewhere [29].
The blot was then reprobed with CUB 7402, as described previously
[30], to visualize tTG. Immunocomplexes were revealed using the
chemiluminescence detection kit (Pierce) according to manufacturer's
instructions.
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Caco-2 cells were seeded on glass coverslips (5×103/cm2) and
3 days later were treated for 15 min at 37 °C with 100 μg/ml gliadin
lissamine-peptides (p31–43 or p57–68). When requested, inhibitors
of endocytosis, such as methyl-β-cyclodextrin (M-β-CD) and ﬁlipin
(Sigma-Aldrich), were added to the medium 15 min before treatment
with peptides. To investigate the effect of anti-tTG antibodies on
gliadin peptide uptake by cells, 2 μg/ml of clone CUB 7402, or clone
2.8, or non-speciﬁc IgG, was added to the medium 15 min before
treatment with peptides. Coverslips were then washed with PBS, cells
were ﬁxed in 3% PFA for 5 min, and, after washing, coverslips were
mounted withMoviol. Confocal images were acquired with a LSM 510
Zeiss microscope. Fluorescence intensity was measured on an area of
5000 μm2, randomly selected for every sample.
2.9. Endocytosis
Caco-2 cells were seeded on glass coverslips (5×103/cm2) and
3 days later used for endocytosis assay. Endocytosis was carried out
with 20 ng/ml EGF-Alexa Fluor 488 (Invitrogen). After washing cells
with cold PBS, EGF-receptors were loaded with the ligand at 4 °C for
1 h. Then cells werewashedwith cold PBS and incubated for 15 min at
37 °C with warm medium containing unlabeled EGF. To investigate
the effect of anti-tTG antibodies, 2 μg/ml clone 2.8 (or CUB 7402) was
added during the incubation at 4 °C. Antibodies were added again
during the incubation at 37 °C. Finally, coverslips were washed with
PBS and cells were ﬁxed with 3% PFA for 10 min. Mounted coverslips
were observed with a LSM 510 Zeiss microscope and confocal images
were acquired. Fluorescence intensity was measured on an area of
5000 μm2, randomly selected for every sample.
2.10. Statistics
Statistical analysis was performed where appropriate by using the
Student's t-test. Differences were considered to be statistically sig-
niﬁcant at pb0.05.Fig. 1. (A) Surface biotinylated proteins immunoprecipitated with clone 2.8, CUB 7402
streptavidin (upper part of the blot). The asterisks (*) indicate a band that has the same mo
(lower part of the blot). (B) Surface tTG staining of unpermeabilized living Caco-2 cells obt3. Results
3.1. Anti-tTG antibodies, as well as gliadin peptides, induce S-phase in
Caco-2 cells
We recently demonstrated that anti-tTG antibodies, as well as
gliadin-peptide 31–43, induce G0→S transition in G0-synchronized
NIH 3T3 ﬁbroblasts [21,22]. In the present study, we investigated
whether Caco-2 cells, which are human epithelial cells that share
several functions with small intestinal enterocytes [31,32], responded
in the same way to tTG antibodies and to gliadin peptides.
First, we veriﬁed that the antibodies we used in this study (the com-
mercial CUB 7402 and the recombinantmini-antibody from a CD patient,
named “clone 2.8”) speciﬁcally recognize cell surface tTG on Caco-2 cells.
Webiotinylatedcell surfaceproteinsandspeciﬁcally immunoprecipitated
tTG from amembrane-enriched fraction. With clone 2.8, we used amore
bland buffer containing Nonidet P-40 to extract proteins, because clone
2.8 is a conformational antibody and only recognizes a native tTG [33].
Fig. 1A shows the proﬁle, in the range of 75–100 kDa, of surface
biotinylated proteins immunoprecipitated with clone 2.8 and CUB 7402.
The control lane shows the proﬁle of surface biotinylated proteins
immunoprecipitated with non-speciﬁc mouse IgG. The asterisks indicate
a band that has the same molecular weight as tTG. We veriﬁed the
identityof thisbandwithprotein tTGby reprobing theblotwithCUB7402
(lower part of the blot). Visualization of the interaction between the
recombinant miniantibody and surface tTG in not-permeabilized living
Caco-2 cells is shown in Fig. 1B. Membrane-bound tTG had a punctuated
distribution andwas prevalently localized at the periphery of cell clusters,
as previously reported for staining with CUB 7402 [21].
Then,we evaluated the S-phase entry of Caco-2 cells,measured in the
presence of increasing concentrations of the commercial clone CUB 7402
and the recombinant mini-antibody clone 2.8. Fig. 2A shows that both
CUB 7402 and clone 2.8 induced BrdU incorporation. CUB 7402wasmost
effective at2.0 μg/ml (54.2±4.8%BrdU incorporation)whereas clone2.8
was most effective at 4.0 μg/ml (50.5±2.1% of BrdU incorporation). The
induction of S-phase entry was speciﬁc because non-speciﬁc IgG did not
induce any effect (40.0±2.6% of BrdU incorporation).and non-speciﬁc mouse IgG and visualized with horseradish peroxidase-conjugated
lecular weight as tTG. Surface tTG was detected after reprobing the blot with CUB 7402
ained with clone 2.8; 40× magniﬁcation. Non-speciﬁc mouse IgG served as control.
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cellular membrane-bound tTG triggers an intracellular response, we
treated Caco-2 cells with 100 μg/ml of CUB 7402 or clone 2.8 for 5 minFig. 2. (A) CUB 7402 (black bars) and clone 2.8 (light gray bars) dose-dependently induced
reported as means±s.d. of at least three independent experiments. (B) Western blot of Cac
phosphorylation after CUB 7402 or Clone 2.8 treatment. Non-speciﬁc mouse IgG and 20% FB
parallel experiments for each stimulus. (C) Induction of S-phase entry of Caco-2 cells by diffe
reported as means+s.d. of three separate experiments.and then performed a Western blot analysis on Caco-2 cell extracts to
visualize ERK-phosphorylation. Non-speciﬁc mouse IgG and 20% FBS
were used as negative control and positive control of the experiment,the S-phase entry of Caco-2 cells. Non-speciﬁc mouse IgG served as control. Data are
o-2 total proteins, stained by ERK or P-ERK antibodies showed a rapid increase of ERK
S served as negative and positive control, respectively. The blot shows the result of two
rent concentrations of p31–43. The effect of 100 μg/ml p57–68 is also reported. Data are
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increased rapidly after brief treatment with clone CUB 7402 or clone
2.8, and with FBS, but was not inﬂuenced by mouse IgG. This ﬁnding
indicates that anti-tTG antibodies mediate out-in cell signaling by
interacting with cell surface tTG.
We next carried out experiments to evaluate whether the toxic
peptide p31–43 and the T-cell immunogenic peptide p57–68 were
able to drive Caco-2 cells into S phase. As shown in Fig. 2C, p31–43
induced BrdU incorporation in Caco-2 cells in a dose-dependent
manner. In fact, BrdU incorporation increased up to about 50% in cells
treated with 100 μg/ml p31–43. Peptide 57–68 did not induce S-
phase entry (40.3±2.1% of BrdU incorporation) when used at a
concentration of 100 μg/ml.
3.2. Anti-tTG antibodies impair the capability of P31–43 to induce Caco-
2 cells into S-phase
Because we found that anti-tTG antibodies and p31–43, but not p57–
68, drive Caco-2 cells into S-phase, we stimulated intestinal cells with
clone2.8 andp31–43 separately and in combination.As reported in Fig. 3,
concentrations of clone 2.8 (2 μg/ml) and p31–43 (100 μg/ml) induced
47.0±1.0% and 48.7±1.5% BrdU incorporation respectively when used
separately and48.3±2.9% BrdU incorporationwhenused together (light
gray bars). This result suggests that anti-tTG antibodies and p31–43
interacted at some level. Thereforewe evaluated the effect of clone 2.8 at
a suboptimal concentration (0.2 μg/ml) combined with p31–43 at a
concentration that induced the highest BrdU incorporation (100 μg/ml).
Under these conditions, BrdU incorporation was reduced to 40.5±0.7%,
which suggests that anti-tTG antibodies, at a suboptimal concentration,
affected p31–43 stimulation (Fig. 3, white bars).We also tested the effect
of clone 2.8 at a concentration that induced the highest BrdUFig. 3. Effect of the simultaneous presence of clone 2.8 and p31–43 on BrdU incorporation by Ca
did not produce an additive or a synergic effect (light gray bars). A suboptimal concentration
suboptimal concentration of p31–43 (20 μg/ml)didnot affect the clone2.8proliferating effect (dincorporation (2.0 μg/ml) combined with a suboptimal concentration
of p31–43 (20 μg/ml). In this case, BrdU incorporation was not affected
(46.0±1.0% versus 47.0±0.8% produced by clone 2.8 alone) (Fig. 3, dark
gray bars) which indicates that p31–43 did not inﬂuence the effects
induced by anti-tTG antibodies. We obtained similar results when we
used the commercial clone CUB 7402 (not shown) instead of clone 2.8.
3.3. Relationship between tTG's extracellular transamidating activity and
the effects evoked by gliadin peptides
Wenext investigated if the transamidating activity associatedwith
the extracellular membrane surface of tTG could be involved in the
modulation of cell cycle progression. To this aim, we carried out an S-
phase entry assay with cystamine, a TG irreversible inhibitor, and
monodansylcadaverine (MDC), a TG competitive substrate. As shown
in Fig. 4A, cystamine did not affect BrdU incorporation. Similarly, MDC
did not induce S-phase entry at any of the concentrations tested
(Fig. 4B); indeed, BrdU incorporation was slightly reduced at 50 μM.
Notably, both amines, like CUB 7402 and clone 2.8, exerted a strong
inhibitory effect in an in vitro enzymatic assay (Fig. 4C).
Finally, we investigated whether cystamine and MDC affected
p31–43-induced S-phase entry. Neither 50 μM cystamine together
with 100 μg/ml p31–43 (light gray bars) nor 10 μMMDCwith 100 μg/
ml p31–43 (dark gray bars) signiﬁcantly inhibited BrdU incorporation
versus p31–43 alone (Fig. 4D).
3.4. Anti-tTG antibodies derange P31–43 (but not P57–68) internalization
by Caco-2 cells
We next evaluated whether anti-tTG antibodies impaired p31–
43's capability to drive Caco-2 cells into S phase by interfering withco-2 cells. Effective concentrations of clone 2.8 and p31–43 (2 and 100 μg/ml, respectively)
of clone 2.8 (0.2 μg/ml) inhibited the p31–43 proliferating effect (white bars), whereas a
ark graybars).Data are reportedasmeans±s.d. of at least three independent experiments.
Fig. 4. Effect of cystamine (A) and MDC (B) on BrdU incorporation by Caco-2 cells. (C) Effect of CUB 7402 (20 μg/ml), clone 2.8 (20 μg/ml), MDC (50 μM) and cystamine (50 μM) on
tTG activity. (D) Effect of the simultaneous presence of cystamine, or MDC, and p31–43 on BrdU incorporation by Caco-2 cells. All data are reported as means±s.d. of at least three
independent experiments.
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mechanisms of transport in Caco-2 cells using lissamine-labeled
p31–43 (p31–43-liss) and p57–68 (p57–68-liss) in the absence and
presence of anti-tTG antibodies.
When we pre-treated Caco-2 cells with M-β-CD, a general
inhibitor of endocytosis, for 15 min and then added p31–43-liss to
the medium and incubated the mix at 37 °C for a further 15 min, p31–
43-liss entry into Caco-2 cells was dramatically reduced (Fig. 5A). On
the contrary, whenwe pre-treated the cells with ﬁlipin, an inhibitor of
lipid raft/caveolae-mediated endocytosis, p31–43-liss entry into
Caco-2 cells was not affected (Fig. 5A). We concluded that p31–43
enters Caco-2 cells by endocytosis and excluded the involvement of
lipid raft/caveolae-mediated endocytosis. As shown in Fig. 5B, when
we pre-treated cells with M-β-CD, p57–68-liss uptake was slightly
reduced, whereas ﬁlipin-pretreatment reduced p57–68-liss uptake in
a more consistent way (Fig. 5B). Thus, under our conditions, p57–68
was endocytosized by Caco-2 cells, probably through a lipid raft/
caveolae-mediated mechanism.
To evaluate whether or not anti-tTG antibodies affect gliadin-
peptide uptake into Caco-2 cells, we carried out peptide uptake
experiments in the presence of CUB 7402 and clone 2.8. As reported in
Fig. 6A, pre-treatment with clone 2.8 (2 μg/ml) resulted in weak p31–
43-liss staining, which indicates that the antibody affected the entry of
p31–43-liss into the cells. A similar effect was obtained with CUB
7402. Conversely, non-speciﬁc IgG did not affect p31–43-liss uptake
(Fig. 6A). Quantiﬁcation of the percent of ﬂuorescence intensity(mean of three experiments) relative to p31–43-liss uptake, in the
presence of clone CUB 7402 or clone 2.8 (2 μg/ml), showed that both
antibodies reduced ﬂuorescence by about 50%, whereas non-speciﬁc
IgG did not affect ﬂuorescence intensity (Fig. 6C). These effects were
less pronounced, but still signiﬁcant, at lower concentration (0.2 μg/
ml and 1.0 μg/ml) of antibodies (Fig. 6C). Pre-treatmentwith clone 2.8
or CUB7402didnot affectp57–68-liss entry intoCaco-2cells (Fig. 6B, C).
In addition, as expected, cystamine and MDC did not affect either p31–
43-liss or p57–68-liss entry into cells (not shown). Interestingly, when
we treated cells with antibodies to β1-integrin (10 μg/ml), which is
non-covalently complexed with tTG on the cell surface [27], p31–43
uptake but not p57–68 uptake was reduced (Fig. 6D).
3.5. Anti-tTG antibodies and endocytosis
To determine how the tTG antibodies interfered with endocytosis,
we studied their effect on EGF internalization by cells evaluated with
the labeled-ligand EGF-Alexa Fluor 488, which is prevalently
internalized by cells through clathrin-mediated endocytosis [34].
After incubation at 0 °C for 1 h with and without clone 2.8 (2 μg/ml),
cells were treated with EFG-Alexa Fluor 488 at 37 °C for 15 min, then
ﬁxed. In the presence of clone 2.8, the number of endocytic vesicles
containing EGF-Alexa Fluor 488 after 15 min of incubation at 37 °C
was lower than in cells not exposed to antibodies (Fig. 7A). To
quantify ﬂuorescence, we measured its intensity relative to a random
area of 5000 μm2 in each coverslip. As shown in Fig. 7B, there was no
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15 min in the presence of clone 2.8. Similar results were obtainedwith
CUB 7402 (Fig. 7B).
4. Discussion
We investigated the relationship between anti-tTG antibodies and
gliadin peptides, both of which are present in the small-intestinal
mucosa of patients in the early phase of CD, probably even at luminal
level. Our results indicate a hitherto unknown role of celiac anti-tTG
antibodies, i.e., they impair the uptake of p31–43, but not of p57–68,
by epithelial cells. We previously reported that celiac anti-tTG
antibodies and α-gliadin p31–43 induce the G0-S transition in murine
ﬁbroblasts and enterocytes from celiac patients [21,22]. We hypoth-
esized that autoantibodies to tTG and gliadin peptides together could
produce an additive or synergic proliferative effect in cells of epithelial
origin. To test our hypothesis, we ﬁrst investigated whether the
response of Caco-2 cells to tTG-antibodies is similar to that of NIH 3T3
cells and of other cells we previously used [21]. Here we report that
both commercial clone CUB 7402 and a recombinant mini-antibody
from a CD patient induce proliferation in Caco-2 cells. Moreover, we
found that p31–43, but not p57–68, induce Caco-2 cell proliferation.
Surprisingly, when we stimulated intestinal cells with effective
concentrations of p31–43 combined with anti-tTG antibodies, there
was no additive effect. On the contrary, suboptimal concentration of
antibodies together with effective concentration of p31–43 inhibited
BrdU incorporation. In conclusion, our results indicate that anti-tTG
antibodies interfered with p31–43 stimulation whereas p31–43 did
not affect the response induced by anti-tTG antibodies.
In an attempt to explain these effects, we investigated the rela-
tionship between tTG-antibodies and gliadin peptide uptake. A critical
step in the pathogenesis of CD is the epithelial handling of gliadin
peptides. It is known that gliadin peptides enter the cells, interactFig. 5. Effect of 10 mM M-β-CD and 5 μg/ml ﬁlipin on p31–43 uptake (A) and p57–68 upta
(more than 3); 63× magniﬁcation.with the vesicular compartment (M.V. Barone, unpublished) and are
transcytosed to the basal part of the cells [23,35]. However, the
mechanism of uptake is not completely understood. Our results on the
comparative uptake of two different gliadin fragments (p31–43 and
p57–68), in the presence of inhibitors of endocytosis, show that p31–
43 and p57–68 act differently in relation to entry into epithelial cells.
M-β-CD is considered a non-speciﬁc inhibitor of endocytosis and can
be used to block all endocytic pathways, whereas the antibiotic ﬁlipin
speciﬁcally blocks lipid raft/caveolae-mediated endocytosis [36–41].
Our confocal images of lissamine-labeled peptides show that both
p31–43 and p57–68 enter Caco-2 cells, but while p57–68 uptake was
reduced by ﬁlipin, which indicates the occurrence of a lipid raft/
caveolae-mediated mechanism, p31–43 uptake was not (Fig. 5).
We also show that anti-tTG-antibodies affect only p31–43 uptake.
This effect is speciﬁc because a non-speciﬁc antibody did not alter the
transport pathway (Fig. 6). Interestingly, anti-β1 integrin antibodies
had a similar effect on p31–43 uptake, which suggests that the tTG-
integrin complex on the cell surface is implicated in the cellular
transport of p31–43 but not of p57–68.
Taken together, our results show that cells handle p31–43 and
p57–68 differently, which is in line with other differences we
identiﬁed between the two peptides. In fact, p31–43 and p57–68
are located in different sites during maturation of endocytic vesicles
both in Caco-2 cells and in intestinal biopsies from CD patients (M.V.
Barone, unpublished) [42]. Staining with markers of the endocytic
pathway showed that p31–43 remains in early endocytic vesicles
whereas p57–68-carrying vesicles mature into late endosomes (M.V.
Barone, unpublished). Furthermore, studies on the interaction of
“toxic” and “immunogenic” gliadin peptides with a membrane-like
environment in vitro showed that only p31–43 was able to bind
micelles, whereas p56–68 did not appear to interact with them [43].
Since gliadin peptides enter the cells by endocytosis and anti-tTG
antibodies interfere with p31–43 entry, we evaluatedwhether anti-tTGke (B) by Caco-2 cells. Representative confocal images of several similar experiments
Fig. 6. Representative confocal images of similar experiments (more than 3); 63×magniﬁcation. Effect of clone 2.8 or CUB 7402 or non-speciﬁc IgG (2 μg/ml) on p31–43 uptake (A) and
p57–68 uptake (B) by Caco-2 cells. (C) Quantiﬁcation of the inhibitory effect of anti-tTG antibodies on p31–43 and p57–68 uptake by Caco-2 cells. The bars represent the percent of
ﬂuorescence intensity calculatedwith respect to liss-peptide uptake in the absence of antibodies (100% of ﬂuorescence intensity). Data are reported asmeans±s.d. of three independent
experiments. Asterisk (*) indicates signiﬁcantly different values (pb0.05). (D) Effect of anti-β1-integrin antibodies (10 μg/ml) on p31–43 and p57–68 uptake by Caco-2 cells.
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Fig. 7. (A) Endocytic vesicles containing EGF-Alexa Fluor 488 were less abundant in Caco-2 cells after incubation at 37 °C for 15 min in the presence of clone 2.8 (2 μg/ml).
Representative confocal images of similar experiments (more than 6); 63× magniﬁcation. (B) Quantiﬁcation of the inhibitory effect of anti-tTG antibodies on EGF-Alexa Fluor 488
uptake by Caco-2 cells. The bars represent the ﬂuorescence intensities relative to six independent experiments.
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which is prevalently internalized by cells through a clathrin-mediated
endocytosis [34], we demonstrate that anti-tTG-antibodies interfere
with endocytosis. These results provide strong evidence that cell surface
tTG is involved in the mechanism of endocytosis. In 1980, Davies et al.
reported that tTG was involved in the mechanism of endocytosis [44].
However, at that time, the existence of an extracellular membrane
bound form of tTG was unknown.We previously suggested [21] that anti-tTG antibodies, by inter-
acting with the extracellular membrane-bound tTG, cause G0→S
transition in synchronized NIH 3T3 ﬁbroblasts through a phosphor-
ylation pathway. We also hypothesized that tTG catalytic activity was
not involved in this process. Although tTG is prevalently an
intracellular enzymemainly localized in the cytosol, relevant amounts
of the protein are present also on the cell surface. Externalized tTG is
in part removed from the cell surface and in part constitutes the pool
726 I. Caputo et al. / Biochimica et Biophysica Acta 1802 (2010) 717–727of the membrane-bound protein [45]. Surface tTG functions often are
independent of catalytic activity. However, the issue is highly debated.
In fact, owing to the availability of high calcium levels and low GTP
concentrations in the extracellular space, tTG should be basically
active, although the effects of anchorage to ﬁbronectin and the actions
of metalloproteinases have not been fully explored. It has been
demonstrated that, being an outside membrane-bound protein, tTG
could mediate the interaction of β1 and β2 integrins with ﬁbronectin
in a catalytic independent manner [27]. Through this interaction, tTG
could modulate cell-matrix adhesion, spreading, integrin-mediated
signaling, and cell migration, proliferation or differentiation
[27,46,47]. Remarkably, the cross-linking activity of tTG is not
required for inhibition of p31–43 uptake or for its proliferating effect.
In fact, neither cystamine nor MDC, which are inhibitors of tTG
catalytic activity, affected peptide entry into Caco-2 cells or cell cycle
progression. In addition, we provide a direct demonstration that the
interaction of tTG antibodies with the extracellular membrane-bound
tTG triggers an intracellular response that leads to a rapid increase of
ERK phosphorylation (Fig. 2B). Therefore, the effects we observed
probably result from the interaction of antibodies with tTG on the cell
surface without the involvement of catalytic activity.
5. Conclusions
The results we report herein show that anti-tTG antibodies
interfere with p31–43 endocytosis, which suggests that cell-surface
tTG could play a hitherto unknown role in the regulation of gliadin
peptide uptake and, more generally, in endocytosis.
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